On October 3, 2022, the U.S. Food and Drug Administration (FDA) approved a 30-second Intravenous (“IV”) Push method of administration for the maintenance dose of Trogarzo (800mg).
In order to provide further dosing convenient to patients and practioners for the administration of Trogarzo, TaiMed’s marketing partner, Theratechnologies Inc. filed a supplemental Biologics License Application (sBLA) to the FDA for the IV Push administration of the loading dose of Trogarzo (2000mg) in July 2024.
The FDA has approved the application.